NO20026119L - Anvendelse av sekretinreseptorligandere i behandling av cystisk fibrose (CF) og kronisk, obstruktiv lungesykdom (COPD) - Google Patents

Anvendelse av sekretinreseptorligandere i behandling av cystisk fibrose (CF) og kronisk, obstruktiv lungesykdom (COPD)

Info

Publication number
NO20026119L
NO20026119L NO20026119A NO20026119A NO20026119L NO 20026119 L NO20026119 L NO 20026119L NO 20026119 A NO20026119 A NO 20026119A NO 20026119 A NO20026119 A NO 20026119A NO 20026119 L NO20026119 L NO 20026119L
Authority
NO
Norway
Prior art keywords
treatment
pulmonary disease
chronic obstructive
obstructive pulmonary
cystic fibrosis
Prior art date
Application number
NO20026119A
Other languages
English (en)
Norwegian (no)
Other versions
NO20026119D0 (no
Inventor
Richard Jon Davis
Keith John Page
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Publication of NO20026119D0 publication Critical patent/NO20026119D0/no
Publication of NO20026119L publication Critical patent/NO20026119L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
NO20026119A 2000-07-04 2002-12-19 Anvendelse av sekretinreseptorligandere i behandling av cystisk fibrose (CF) og kronisk, obstruktiv lungesykdom (COPD) NO20026119L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016441.8A GB0016441D0 (en) 2000-07-04 2000-07-04 Therapeutic method
PCT/GB2001/002989 WO2002002134A1 (en) 2000-07-04 2001-07-04 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd)

Publications (2)

Publication Number Publication Date
NO20026119D0 NO20026119D0 (no) 2002-12-19
NO20026119L true NO20026119L (no) 2003-02-25

Family

ID=9895021

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20026119A NO20026119L (no) 2000-07-04 2002-12-19 Anvendelse av sekretinreseptorligandere i behandling av cystisk fibrose (CF) og kronisk, obstruktiv lungesykdom (COPD)
NO20061667A NO328406B1 (no) 2000-07-04 2006-04-12 Anvendelse av camostat for fremstilling av et medikament for behandling av cystisk fibrose (CF) og sammensetning som omfatter camostat sammen med minst en annen forbindelse som er aktiv mot CF

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20061667A NO328406B1 (no) 2000-07-04 2006-04-12 Anvendelse av camostat for fremstilling av et medikament for behandling av cystisk fibrose (CF) og sammensetning som omfatter camostat sammen med minst en annen forbindelse som er aktiv mot CF

Country Status (20)

Country Link
US (4) US6780839B2 (xx)
EP (2) EP1736153B1 (xx)
JP (2) JP2004501977A (xx)
KR (2) KR100881931B1 (xx)
CN (2) CN100584324C (xx)
AT (1) ATE454145T1 (xx)
AU (1) AU2001267729A1 (xx)
CA (1) CA2412839A1 (xx)
CY (1) CY1109937T1 (xx)
DE (1) DE60141054D1 (xx)
DK (1) DK1736153T3 (xx)
ES (1) ES2341562T3 (xx)
GB (3) GB0016441D0 (xx)
HK (1) HK1104959A1 (xx)
MX (1) MXPA02012755A (xx)
NO (2) NO20026119L (xx)
NZ (1) NZ523303A (xx)
PT (1) PT1736153E (xx)
WO (1) WO2002002134A1 (xx)
ZA (1) ZA200210268B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CN100407816C (zh) * 2005-07-07 2008-07-30 华为技术有限公司 一种群组呼叫的寻呼方法
US8473250B2 (en) 2006-12-06 2013-06-25 Solaredge, Ltd. Monitoring of distributed power harvesting systems using DC power sources
US11569659B2 (en) 2006-12-06 2023-01-31 Solaredge Technologies Ltd. Distributed power harvesting systems using DC power sources
EP2185172A2 (en) * 2007-09-11 2010-05-19 Mondobiotech Laboratories AG Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
US20100184676A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of a peptide as a therapeutic agent
US11318190B2 (en) * 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
RU2721415C1 (ru) * 2019-09-16 2020-05-19 Федеральное государственное бюджетное научное учреждение Дальневосточный научный центр физиологии и патологии дыхания" Способ прогнозирования эффективности коррекции холодовой гиперреактивности дыхательных путей у больных бронхиальной астмой при применении экстрамелкодисперсного аэрозоля для ингаляций беклометазона дипропионата/формотерола фумарата
WO2022065860A1 (ko) * 2020-09-24 2022-03-31 충북대학교 산학협력단 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
RU2770282C1 (ru) * 2021-07-26 2022-04-15 Федеральное государственное бюджетное научное учреждение «Дальневосточный научный центр физиологии и патологии дыхания» Способ диагностики варианта холодовой гиперреактивности дыхательных путей у больных бронхиальной астмой

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) * 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
GB1472700A (en) * 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
DE3402466A1 (de) * 1984-01-25 1985-08-01 Hoechst Ag, 6230 Frankfurt Sekretin und dieses enthaltende mittel zur prophylaxe des aspirations-syndroms
ATE101619T1 (de) * 1990-06-26 1994-03-15 Sanwa Kagaku Kenkyusho Co Vip-analogen und ihre verwendung.
GB9318105D0 (en) 1993-09-01 1993-10-20 Medical Res Council Receptor action
AU709559B2 (en) 1994-04-07 1999-09-02 Proteinix Company Vasoactive intestinal polypeptide
ZA971607B (en) 1996-03-12 1998-08-25 Univ Johns Hopkins Methods of treatment of allergic diseases
JPH09309873A (ja) * 1996-05-22 1997-12-02 Jiyunsei Kagaku Kk メシル酸カモスタットの新規な製造法
WO1998002453A2 (en) 1996-07-15 1998-01-22 Universite Libre De Bruxelles Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
JP2002501616A (ja) * 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
US6020314A (en) * 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20040191238A1 (en) 2004-09-30
KR20030026967A (ko) 2003-04-03
KR20060040754A (ko) 2006-05-10
US20060147384A1 (en) 2006-07-06
CA2412839A1 (en) 2002-01-10
CN100584324C (zh) 2010-01-27
DK1736153T3 (da) 2010-05-10
EP1736153A2 (en) 2006-12-27
GB2368795B (en) 2004-08-04
CN1923187A (zh) 2007-03-07
AU2001267729A1 (en) 2002-01-14
EP1736153B1 (en) 2010-01-06
GB2397522B (en) 2004-09-22
EP1296708A1 (en) 2003-04-02
PT1736153E (pt) 2010-03-24
KR100881931B1 (ko) 2009-02-06
GB2397522A (en) 2004-07-28
NO20026119D0 (no) 2002-12-19
JP2006213728A (ja) 2006-08-17
NO328406B1 (no) 2010-02-15
GB2368795A (en) 2002-05-15
GB0409577D0 (en) 2004-06-02
WO2002002134A1 (en) 2002-01-10
ES2341562T3 (es) 2010-06-22
US20110039759A1 (en) 2011-02-17
NO20061667L (no) 2002-01-07
US6780839B2 (en) 2004-08-24
ZA200210268B (en) 2003-10-28
US20020142956A1 (en) 2002-10-03
CY1109937T1 (el) 2014-09-10
JP2004501977A (ja) 2004-01-22
ATE454145T1 (de) 2010-01-15
NZ523303A (en) 2004-11-26
EP1736153A3 (en) 2007-05-23
GB0016441D0 (en) 2000-08-23
HK1104959A1 (en) 2008-02-01
CN1452494A (zh) 2003-10-29
GB0200416D0 (en) 2002-02-27
MXPA02012755A (es) 2004-09-10
DE60141054D1 (de) 2010-02-25

Similar Documents

Publication Publication Date Title
NO20061667L (no) Anvendelse av camostat for behandling av cystisk fibrose (CF) og kronisk, obstruktiv lungesykdom (COPD)
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
NO20032036L (no) Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser
DK1360202T3 (da) Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
DK1462100T3 (da) Præparat, der omfatter formoterol og et glucocorticosteroid
NO20001401L (no) Ny anvendelse av budesonid og formoterol
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
PT1333887E (pt) Metodo de tratamento de desordens musculares
EE200000068A (et) Akuutse kopsukahjustuse ja -fibroosi ravi avß6 antagonistidega
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
AU2001252192A1 (en) Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd)
NO20012831D0 (no) Diazepinoindoler for behandling av kronisk obstruktiv lungesykdom
HK1038703A1 (zh) 糖皮質類固醇在制備治療輕度/早期copd(慢性阻塞性肺病)的藥物中的應用
RU2001115900A (ru) Способ лечения туберкулеза легких
IS7029A (is) 4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
ZA200308631B (en) 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
AU4335901A (en) Novel therapeutic treatment of chronic obstructive pulmonary disease
DE60019104D1 (de) Gentherapy von lungenkrankheiten
IS7031A (is) 4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
DK1411936T3 (da) Anvendelse af thiazolderivater i fremstillingen af et medikament til behandling af kronisk obstruktiv lungesygdom
IS7033A (is) 4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IL136663A0 (en) Use of substituted amino compounds in the treatment of chronic obstructive pulmonary disease
IL158809A0 (en) The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
SI1257254T1 (sl) Farmacevtske oblike, ki vsebujejo antiholinergicno zdravilo za zdravljenje kronicne obstruktivne bolezni pljuc
RU98114654A (ru) Способ лечения туберкулеза легких

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application